Prucalopride: A new drug for the treatment of chronic constipation

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 4, 2009, Pages 337-343

  Tack, Jan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

5 hydroxytryptamine 4; Chronic constipation; Efficacy; Enterokinetic; Prucalopride; Receptor agonist; Safety

Indexed keywords

CISAPRIDE; LAXATIVE; MOSAPRIDE CITRATE; PLACEBO; POTASSIUM CHANNEL HERG; PRUCALOPRIDE; R 108512; RENZAPRIDE; SEROTONIN 4 AGONIST; SEROTONIN 4 ANTAGONIST; SEROTONIN 4 RECEPTOR; TEGASEROD; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; GASTROINTESTINAL MOTILITY; HEART ARRHYTHMIA; HEART RATE; HUMAN; ILEUS; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; QT INTERVAL; SCLERODERMA; SIDE EFFECT; STOMACH EMPTYING; VOMITING;

ANIMALS; BENZOFURANS; CHRONIC DISEASE; CONSTIPATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN AGONISTS; TREATMENT OUTCOME;

EID: 70049101578     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.38     Document Type: Article

References (57)

1. Lembo A, Camilleri M. Chronic constipation. N. Engl. J. Med. 349(14), 1360-1368 (2003).
2. Pare P, Ferrazzi S, Thompson W et al. An epidemiological survey of constipation in Canada, definitions, rates, demographics and predictors of health care seeking. Am. J. Gastroenterol. 96, 3130-3137 (2001).
3. Longstreth G, Thompson W, Chey W, Houghton L, Mearin F, Spiller R. Functional bowel disorders. Gastroenterology 130(5), 1480-1491 (2006).
4. Bracco A, Kahler K. Burden of chronic constipation must include estimates of work productivity and activity impairment in addition to traditional healthcare utilization. Am. J. Gastroenterol. 99(Suppl. 10), S233 (2004).
5. Irvine EJ, Ferrazzi S, Pare P, Thompson WG, Ranee L. Health-related quality of life in functional GI disorders, focus on constipation and resource utilization. Am. J. Gastroenterol. 97(8), 1986-1993 (2002).
6. American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am. J. Gastroenterol. 100, S1-S4 (2005).
7. Tack J, Müller-Lissner S. Treatment of chronic constipation, current pharmacologic approaches and future directions. Clin. Gastroenterol. Hepatol. 7(5), 502-508 (2008).
8. Talley NJ. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol. Motil. 20(Suppl. 1), 121-129 (2008).
9. Gardner VY, Beckwith JV, Heyneman CA. Cisapride for the treatment of chronic idiopathic constipation. Ann. Pharmacother. 29(11), 1161-1163 (1995).
10. Tack J, Müller-Lissner S, Bytzer P et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 54(12), 1707-1713 (2005).
11. Kamm MA, Müller-Lissner S, Talley NJ et al. Tegaserod for the treatment of chronic constipation, a randomized, double-blind, placebo-controlled multinational study. Am. J. Gastroenterol. 100(2), 362-372 (2005).
12. 3 antagonist, ameliorates constipation in Parkinsonian patients. Mov. Disord. 20(6), 680-686 (2005).
13. Tack J, Middleton SJ, Horne MC et al. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol. Ther. 23(11), 1655-1665 (2006).
14. Scarpellini E, Tack J. Renzapride, a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opin. Investig. Drugs (11), 1663-1670 (2008).
15. 4 receptor agonists, similar but not the same. Neurogastroenterol. Motil. 20(2), 99-112 (2008).
16. 4) positively coupled to adenylate cyclase in neurons. Naunyn Schmiedebergs Arch. Pharmacol. 340, 403-410 (1989).
17. 4 receptor activation. Br. J. Pharmacol. 102, 563-564 (1991).
18. Briejer MR, Bosmans JP, Van Daele P et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur. J. Pharmacol. 423(1), 71-83 (2001).
19. LePard KJ, Ren J, Galligan JJ. Presynaptic modulation of cholinergic and non-cholinergic fast synaptic transmission in the myenteric plexus of guinea-pig ileum. Neurogastroenterol. Motil. 16(3), 355-364 (2004).
20. 4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br. J. Pharmacol. 127(6), 1431-1437 (1999).
21. Prins NH, Shankley NP, Welsh NJ et al. An improved in vitro bioassay for the study of 5-HT(4) receptors in the human isolated large intestinal circular muscle. Br. J. Pharmacol. 129(8), 1601-1608 (2000).
22. 4 receptors located on cholinergic nerves in human colon circular muscle. Neurogastroenterol. Motil. 17(3), 366-375 (2005).
23. 4 receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle. Br. J. Pharmacol. 131(5), 927-932 (2000).
24. 4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle. Neurogastroenterol. Motil. 18(9), 853-861 (2006).
25. 4 receptors mediating enhancement of contractility in canine stomach; an in vitro and in vivo study. Br. J. Pharmacol. 132(8), 1941-1947 (2001).
26. 4 receptor agonists at gastric versus cardiac receptors, an operational framework to explain and quantify organ-specific behavior. J. Pharmacol. Exp. Ther. 317(3), 955-964 (2006).
27. Leclere PG, Lefebvre RA. Presynaptic modulation of cholinergic neurotransmission in the human proximal stomach. Br. J. Pharmacol. 135(1), 135-142 (2002).
28. Qi HB, Luo JY, Liu X. Effect of enterokinetic prucalopride on intestinal motility in fast rats. World J. Gastroenterol. 9(9), 2065-2067 (2003).
29. De Winter BY, Boeckxstaens GE, De Man JG et al. Effect of different prokinetic agents and a novel enterokinetic agent on postoperative ileus in rats. Gut 45(5), 713-718 (1999).
30. Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol. Motil 13(5), 465-472 (2001).
31. Emmanuel AV, Kamm MA, Roy AJ, Antonelli K. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut 42(4), 511-516 (1998).
32. 4 agonist, prucalopride, in healthy humans. Gut 44(5), 682-686 (1999).
33. Poen AC, Felt-Bersma RJ, Van Dongen PA, Meuwissen SG. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol. Ther. 13(11), 1493-1497 (1999).
34. 4 receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol. Ther. 16(3), 603-612 (2002).
35. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 120(2), 354-360 (2001).
36. Sloots CE, Poen AC, Kerstens R et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol. Ther. 16(4), 759-767 (2002).
37. + channel. J. Pharmacol. Exp. Ther. 299(3), 1007-1012 (2001).
38. + channel and the common T897 polymorph. Eur. J. Pharmacol. 554(2-3), 98-105 (2007).
39. + channel by the gastrointestinal prokinetic agent cisapride. Am. J. Physiol. 273(5 Pt 2), H2534-H2538 (1997).
40. Rampe D, Roy ML, Dennis A, Brown AM. Mechanism for the proarrhythmic effects of cisapride (Propulsid), high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett. 417(1), 28-32 (1997).
41. Pau D, Workman AJ, Kane KA, Rankin AC. Electrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with β-adrenoceptor antagonists. J. Pharmacol. Exp. Ther. 313(1), 146-153 (2005).
42. 4 receptor-mediated response in pig atrium but not in stomach. Br. J. Pharmacol. 156(2), 362-376 (2009).
43. Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am. J. Gastroenterol. 97(1), 194-197 (2002).
44. Boyce MJ, Carey W, Mannaert EJ, Mertens A, Ausma J. Cardiovascular safety of prucalopride (Resolor ®) in healthy subjects, results from a randomized, double-blind, placebo-controlled, cross-over trial. Gastroenterology 134, A551 (2008).
45. Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 67(1-2), 82-89 (2003).
46. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 58(3), 357-365 (2009).
47. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N. Engl. J. Med. 358(22), 2344-2354 (2008).
48. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial, the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol. Ther. 29(3), 315-328 (2009).
49. Frank L, Kleinman L, Farup C, Taylor L, Miner P Jr. Psychometric validation of a constipation symptom assessment questionnaire. Scand. J. Gastroenterol. 34(9), 870-877 (1999).
50. Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand. J. Gastroenterol. 40(5), 540-551 (2005).
51. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 45(Suppl. 2), II43-II47 (1999).
52. Camilleri M, Gryp RS, Kerstens R et al. Efficacy of prucalopride (Resolor (R)) in patients with chronic constipation, pooled data from three pivotal Phase III studies. Gastroenterology 134, A548 (2008).
53. Mueller-Lissner SA, Rykx A, Kerstens R et al. Randomized double-blind placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor (R)) in elderly patients with chronic constipation. Gastroenterology 134, A157 (2008).
54. Krogh K, Jensen MB, Gandrup P, Laurberg S, Nilsson J, Kerstens R, De Pauw M. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand. J. Gastroenterol. 37, 431-436 (2002).
55. Gatandiuk S, Beyens G, Ausma J et al. Evaluation of the efficacy safety and tolerability of prucalopride (Resolor (R)) given subcutaneously in patients undergoing elective partial colectomies. Gastroenterology 134, A138 (2008).
56. Tack J, Ausma J, Kerstens R et al. Safety and tolerability of prucalopride (Resolor ®) in patients with chronic constipation, pooled data from three pivotal Phase III studies. Gastroenterology 134, A530 (2008).
57. Van Outryve MJ, Beyens G, Kerstens R, Vandeplassche L. Long-term follow-up study of oral prucalopride administerd to patients with chronic constipation. Gastroenterology 134, A547 (2008).